AstraZeneca lifts 2024 revenue and profit forecast
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines. The London-listed company now expects 2024 revenue and core earnings per share to grow by high teens percentage,